Pharm-Olam: Phase III Pulmonary Arterial Hypertension study completed

Pharm-Olam was selected to provide development services for a Phase III study, which was designed to address the efficacy and safety for a compound for pulmonary arterial hypertension patients.

Pharm-Olam was responsible for:

• The recruitment of 192 patients
• Management of 17 sites in Russia, Belarus, and Ukraine
• All regulatory, project management, and monitoring services

To view the case study and the lessons learned in this study, click here